These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35736563)

  • 1. Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.
    Kalra R; Chen CH; Wang J; Salam AB; Dobrolecki LE; Lewis A; Sallas C; Yates CC; Gutierrez C; Karanam B; Anurag M; Lim B; Ellis MJ; Kavuri SM
    Cancer Res; 2022 Aug; 82(16):2928-2939. PubMed ID: 35736563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer.
    Marín A; Mamun AA; Patel H; Akamatsu H; Ye D; Sudhan DR; Eli L; Marcelain K; Brown BP; Meiler J; Arteaga CL; Hanker AB
    Cancer Res; 2023 Sep; 83(18):3145-3158. PubMed ID: 37404061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined Blockade of Activating
    Croessmann S; Formisano L; Kinch LN; Gonzalez-Ericsson PI; Sudhan DR; Nagy RJ; Mathew A; Bernicker EH; Cristofanilli M; He J; Cutler RE; Lalani AS; Miller VA; Lanman RB; Grishin NV; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(1):277-289. PubMed ID: 30314968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The uncharted role of HER2 mutant alleles in breast cancer.
    Kalra R; Lim B; Ellis MJ; Kavuri SM
    Oncotarget; 2023 Oct; 14():904-907. PubMed ID: 37921670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
    Koga T; Kobayashi Y; Tomizawa K; Suda K; Kosaka T; Sesumi Y; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Suzuki M; Jänne PA; Mitsudomi T
    Lung Cancer; 2018 Dec; 126():72-79. PubMed ID: 30527195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Acquired
    Hanker AB; Brewer MR; Sheehan JH; Koch JP; Sliwoski GR; Nagy R; Lanman R; Berger MF; Hyman DM; Solit DB; He J; Miller V; Cutler RE; Lalani AS; Cross D; Lovly CM; Meiler J; Arteaga CL
    Cancer Discov; 2017 Jun; 7(6):575-585. PubMed ID: 28274957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Determinants of Response to HER Kinase Inhibition in
    Smyth LM; Piha-Paul SA; Won HH; Schram AM; Saura C; Loi S; Lu J; Shapiro GI; Juric D; Mayer IA; Arteaga CL; de la Fuente MI; Brufksy AM; Spanggaard I; Mau-Sørensen M; Arnedos M; Moreno V; Boni V; Sohn J; Schwartzberg LS; Gonzàlez-Farré X; Cervantes A; Bidard FC; Gorelick AN; Lanman RB; Nagy RJ; Ulaner GA; Chandarlapaty S; Jhaveri K; Gavrila EI; Zimel C; Selcuklu SD; Melcer M; Samoila A; Cai Y; Scaltriti M; Mann G; Xu F; Eli LD; Dujka M; Lalani AS; Bryce R; Baselga J; Taylor BS; Solit DB; Meric-Bernstam F; Hyman DM
    Cancer Discov; 2020 Feb; 10(2):198-213. PubMed ID: 31806627
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
    Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
    Sudhan DR; Guerrero-Zotano A; Won H; González Ericsson P; Servetto A; Huerta-Rosario M; Ye D; Lee KM; Formisano L; Guo Y; Liu Q; Kinch LN; Red Brewer M; Dugger T; Koch J; Wick MJ; Cutler RE; Lalani AS; Bryce R; Auerbach A; Hanker AB; Arteaga CL
    Cancer Cell; 2020 Feb; 37(2):183-199.e5. PubMed ID: 31978326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
    Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
    Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
    Robichaux JP; Elamin YY; Vijayan RSK; Nilsson MB; Hu L; He J; Zhang F; Pisegna M; Poteete A; Sun H; Li S; Chen T; Han H; Negrao MV; Ahnert JR; Diao L; Wang J; Le X; Meric-Bernstam F; Routbort M; Roeck B; Yang Z; Raymond VM; Lanman RB; Frampton GM; Miller VA; Schrock AB; Albacker LA; Wong KK; Cross JB; Heymach JV
    Cancer Cell; 2019 Oct; 36(4):444-457.e7. PubMed ID: 31588020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
    Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S
    J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
    Kim JY; Lee E; Park K; Jung HH; Park WY; Lee KH; Sohn J; Lee KS; Jung KH; Kim JH; Lee KH; Im SA; Park YH
    Int J Cancer; 2019 Sep; 145(6):1669-1678. PubMed ID: 30720867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
    Park YH; Lee KH; Sohn JH; Lee KS; Jung KH; Kim JH; Lee KH; Ahn JS; Kim TY; Kim GM; Park IH; Kim SB; Kim SH; Han HS; Im YH; Ahn JH; Kim JY; Kang J; Im SA
    Int J Cancer; 2018 Dec; 143(12):3240-3247. PubMed ID: 29978467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
    Takeda T; Yamamoto H; Suzawa K; Tomida S; Miyauchi S; Araki K; Nakata K; Miura A; Namba K; Shien K; Soh J; Shien T; Kitamura Y; Sendo T; Toyooka S
    Cancer Sci; 2020 Mar; 111(3):849-856. PubMed ID: 31856375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.
    Cheng X; Sun Y; Highkin M; Vemalapally N; Jin X; Zhou B; Prior JL; Tipton AR; Li S; Iliuk A; Achilefu S; Hagemann IS; Edwards JR; Bose R
    Cancer Res; 2023 Sep; 83(17):2839-2857. PubMed ID: 37272756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.
    Ben-Baruch NE; Bose R; Kavuri SM; Ma CX; Ellis MJ
    J Natl Compr Canc Netw; 2015 Sep; 13(9):1061-4. PubMed ID: 26358790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating HER2 mutations in HER2 gene amplification negative breast cancer.
    Bose R; Kavuri SM; Searleman AC; Shen W; Shen D; Koboldt DC; Monsey J; Goel N; Aronson AB; Li S; Ma CX; Ding L; Mardis ER; Ellis MJ
    Cancer Discov; 2013 Feb; 3(2):224-37. PubMed ID: 23220880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway.
    Smith AE; Ferraro E; Safonov A; Morales CB; Lahuerta EJA; Li Q; Kulick A; Ross D; Solit DB; de Stanchina E; Reis-Filho J; Rosen N; Arribas J; Razavi P; Chandarlapaty S
    Nat Commun; 2021 Nov; 12(1):6667. PubMed ID: 34795269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.